Kyverna Therapeutics Inc. (KYTX)
NASDAQ: KYTX
· Real-Time Price · USD
3.53
-0.01 (-0.28%)
At close: Aug 15, 2025, 3:59 PM
3.58
1.42%
After-hours: Aug 15, 2025, 06:09 PM EDT
Kyverna Therapeutics Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
Revenue | n/a | n/a | 2.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 282K |
Cost of Revenue | 515K | 501K | 563K | 558K | 530K | 482K | 462K | 438K | 413K | 8.71M | 374K |
Gross Profit | -515K | -501K | -563K | -558K | -530K | -482K | -462K | -438K | -413K | -8.71M | -92K |
Operating Income | -44.41M | -47.41M | -41.04M | -38.77M | -33.44M | -29.36M | -21.38M | -16.28M | -13.3M | -11.45M | -8.78M |
Interest Income | 2.36M | 2.83M | 3.58M | 4.36M | 4.69M | 2.73M | 789K | 880K | 264K | 349K | 297K |
Pretax Income | -42.08M | -44.63M | -37.49M | -34.49M | -28.8M | -26.69M | -20.67M | -15.46M | -13.09M | -11.14M | -8.5M |
Net Income | -42.08M | -44.63M | -37.49M | -34.49M | -28.8M | -26.69M | -20.67M | -15.46M | -13.09M | -11.14M | -8.5M |
Selling & General & Admin | 8.59M | 9.97M | 7.56M | 9.58M | 6.11M | 6.88M | 4.21M | 2.64M | 2.9M | 2.73M | 1.99M |
Research & Development | 35.82M | 37.43M | 33.48M | 29.19M | 27.32M | 22.48M | 17.16M | 13.21M | 9.99M | 8.71M | 7.07M |
Other Expenses | n/a | -501K | -563K | n/a | n/a | -26K | -32K | -13K | -7K | -3K | 23K |
Operating Expenses | 44.41M | 46.91M | 40.48M | 38.77M | 33.44M | 29.36M | 21.38M | 15.84M | 12.89M | 11.45M | 9.06M |
Interest Expense | 14K | 25K | 27K | 32K | 39K | 44K | 47K | 50K | 46K | 44K | 41K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 44.41M | 47.41M | 41.04M | 38.77M | 33.44M | 29.36M | 21.38M | 16.28M | 13.3M | 11.45M | 9.06M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | 18K | 15K | n/a | n/a | 41K | 64K |
Shares Outstanding (Basic) | 43.23M | 43.22M | 43.21M | 43.16M | 43.13M | 23.75M | 43.12M | 43.12M | 43.12M | 25.8M | 43.12M |
Shares Outstanding (Diluted) | 43.23M | 43.22M | 43.21M | 43.16M | 43.13M | 23.75M | 43.12M | 43.12M | 43.12M | 25.8M | 43.12M |
EPS (Basic) | -0.97 | -1.03 | -0.87 | -0.8 | -0.67 | -1.12 | -0.48 | -0.36 | -0.3 | -0.43 | -0.2 |
EPS (Diluted) | -0.97 | -1.03 | -0.87 | -0.8 | -0.67 | -1.12 | -0.48 | -0.36 | -0.3 | -0.43 | -0.2 |
EBITDA | -44.41M | -47.41M | -36.9M | -33.9M | -28.23M | -26.17M | -20.16M | -14.98M | -12.63M | -10.71M | -8.08M |
EBIT | -42.07M | -44.61M | -37.46M | -34.46M | -28.76M | -26.65M | -20.62M | -15.41M | -13.04M | -11.1M | -8.46M |
Depreciation & Amortization | n/a | 501K | 563K | 558K | 530K | 482K | 462K | 438K | 413K | 394K | 374K |